Tumor-derived microvesicles (TD-MVs) produced under hypoxic conditions are enriched in transforming growth factor beta 1 (TGFB1) and miR-23a, and hence suppress NK cell activity upon uptake by downregulating NK cell-activating receptors (Box 1) as well as the effector molecule lysosomal-associated membrane protein 1 (LAMP1, best known as CD107a) [92]. The gene discussed is TGFB1; the disease is neoplasm.